APP

APP Molekülinformation

Englischer Name	Beta amyloid A4 protein	Anzahl der inverkehr gebrachten Arzneimittel	13
Anzahl der klinischen Arzneimittel	52	Target-Alias	Beta-CTF，Amyloid Beta Precursor Protein，Cerebral Vascular Amyloid Peptide，Beta-Amyloid Precursor Protein，Amyloid-Beta A4 Protein，Beta-Amyloid Peptide，Alzheimer Disease，CTFgamma，ABETA，AAA，PN2，Amyloid beta-Peptides，Amyloid intracellular domain 57，APP，Amyloid intracellular domain 59，PN-II，Alpha-secretase C-terminal fragment，AICD-50，S-APP-alpha，A4，S-APP-beta，Alzheimer disease amyloid protein，Abeta40，Gamma-CTF(59)，Abeta42，Gamma-CTF(57)，Alpha-CTF，Amyloid intracellular domain 50，AID(59)，Gamma-CTF(50)，AID(57)，Beta-secretase C-terminal fragment，Amyloid-beta precursor protein，Amyloid precursor protein，AD1，AICD-57，Beta-APP42，APPI，Beta-APP40，AID(50)，CVAP，AICD-59，Amyloid Beta (A4) Precursor Protein，Peptidase Nexin-II，Protease Nexin-II，PreA4，ABPP，Testicular Tissue Protein Li 2，Beta-Amyloid Peptide(1-40)，Beta-Amyloid Peptide(1-42)，Amyloid Beta A4 Protein
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Beta amyloid A4 protein
Target-Alias	Beta-CTF，Amyloid Beta Precursor Protein，Cerebral Vascular Amyloid Peptide，Beta-Amyloid Precursor Protein，Amyloid-Beta A4 Protein，Beta-Amyloid Peptide，Alzheimer Disease，CTFgamma，ABETA，AAA，PN2，Amyloid beta-Peptides，Amyloid intracellular domain 57，APP，Amyloid intracellular domain 59，PN-II，Alpha-secretase C-terminal fragment，AICD-50，S-APP-alpha，A4，S-APP-beta，Alzheimer disease amyloid protein，Abeta40，Gamma-CTF(59)，Abeta42，Gamma-CTF(57)，Alpha-CTF，Amyloid intracellular domain 50，AID(59)，Gamma-CTF(50)，AID(57)，Beta-secretase C-terminal fragment，Amyloid-beta precursor protein，Amyloid precursor protein，AD1，AICD-57，Beta-APP42，APPI，Beta-APP40，AID(50)，CVAP，AICD-59，Amyloid Beta (A4) Precursor Protein，Peptidase Nexin-II，Protease Nexin-II，PreA4，ABPP，Testicular Tissue Protein Li 2，Beta-Amyloid Peptide(1-40)，Beta-Amyloid Peptide(1-42)，Amyloid Beta A4 Protein
Anzahl der inverkehr gebrachten Arzneimittel	13
Anzahl der klinischen Arzneimittel	52
Höchste Forschungs- und Entwicklungsphase	Approved

APP Produktliste

Attribut
Protein (5)Cell (1)
Produktbibliothek
Online (6)
Spezies
Mouse (1)Human (5)
Etikett
His Tag (5)GFP Tag (1)
Marker
Unconjugated (5)- (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Vorbestellen/Bestellen
HOT APP-H52H5	Human	HEK293	Human APP / SAPPbeta Protein, His Tag (MALS verified)	In den Warenkorb legen
HOT APP-M52H3	Mouse	HEK293	Mouse APP / N-APP Protein, His Tag (MALS verified)	In den Warenkorb legen
APP-H51H6	Human	E. coli	Human APP / Abeta42 Protein, His Tag	In den Warenkorb legen
APP-H51H9	Human	E. coli	Human APP / Abeta40 (672-711) Protein, His Tag	In den Warenkorb legen
APP-H52H3	Human	HEK293	Human APP Protein, His Tag (active enzyme, MALS verified)	In den Warenkorb legen
CHEK-ATP081	Human	HEK293	HEK293/Human APP (GFP) Stable Cell Line	In den Warenkorb legen

Gesamtmenge6

APP Molekülhintergrund

Amyloid precursor protein (APP) is a type I integral membrane protein ubiquitously expressed in many tissues and concentrated in the synapses of neurons. It has three predominant splice variants: APP695, APP751, and APP770. The majority of APP is cleaved at the plasma membrane by the α-secretase in the non-amyloidogenic pathway. The amyloidogenic pathway starts with β-secretase cleavage by BACE1 on the N-terminal part of the Aβ domain, releasing sAPPβ from a membrane-anchored fragment named βCTF or C99, which is subsequently cleaved by γ-secretase to release Aβ.

APP Molekülalias

ABPP,APPI,Amyloid-beta A4 protein

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Buntanetap	ANVS-405; ANVS-401	Phase 3 Clinical	Raptor Pharmaceutical	Alzheimer Disease; Chronic Traumatic Encephalopathy; Cognitive Dysfunction; Down Syndrome; Frontotemporal Dementia; Parkinson Disease	Details
Gantenerumab	MAb-31; R-1450; RG-1450; R-04909832	Phase 3 Clinical	Chugai Pharmaceutical Co Ltd	Alzheimer Disease; Dementia	Details
Valiltramiprosate	BLU-8499; NRM-8499; ALZ-801	Phase 3 Clinical	Alzheon Inc	Alzheimer Disease	Details
Solanezumab	LY-2062430	Phase 3 Clinical	Eli Lilly And Company	Alzheimer Disease; Cognition Disorders; Dementia	Details
Tramiprosate	3-APS; NC-531; NC-758	Phase 3 Clinical	Bellus Health Inc	Alzheimer Disease; Glaucoma; Neurodegenerative Diseases; Stroke	Details
Remternetug	LY-3372993; LY3372993	Phase 3 Clinical	Eli Lilly And Company	Alzheimer Disease; Dementia	Details
[F-18]Flornaptitril	[F-18]FDDNP; F-18-FNT-PET	Phase 3 Clinical	University Of California At Los Angeles	Alzheimer Disease; Chronic Traumatic Encephalopathy	Details
F-18 Florbetazine		Phase 3 Clinical	Hta Co Ltd	Alzheimer Disease	Details
RP-902	RP902; RP-902	Phase 3 Clinical	Risen (Suzhou) Pharma Tech Co Ltd	Alzheimer Disease	Details
Trontinemab	RO-7126209; RG-6102	Phase 3 Clinical	F. Hoffmann-La Roche Ltd	Alzheimer Disease	Details
GAL-101	EG-030; GAL-101; MRZ-99030	Phase 2 Clinical	Tel Aviv University Trust	Geographic Atrophy; Glaucoma	Details
L-clausenamide		Phase 2 Clinical	Fuan Pharmaceutical (Group) Co Ltd, Guangzhou Nuohao Pharmaceutical Technology Co Ltd, Institue Of Materia Medica Chinese Academy Of Medical Science, Qingdao Huanghai Pharmaceutical Co Ltd	Cognitive Dysfunction; Dementia; Memory Disorders	Details
Crenezumab	MABT-5102-A; RG-7412; R-7412; RO-5490245	Phase 2 Clinical	Ac Immune Sa	Alzheimer Disease	Details
(-)-Epigallocatechin gallate	AB-4166	Phase 2 Clinical	Charite Universitaetsmedizin Berlin	Alzheimer Disease; Colonic Neoplasms; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Frailty; Glaucoma, Open-Angle; Huntington Disease; Hypertension; Idiopathic Pulmonary Fibrosis; Inflammation; Insulin Resistance; Leukemia; Liver Cirrhosis; Lung Diseases, Interstitial; Multiple Sclerosis, Relapsing-Remitting; Muscular Dystrophy, Duchenne; Neoplasms; Obesity; Ocular Hypertension; Papillomavirus Infections; Parkinson Disease; Peripheral Nervous System Diseases; Prostatic Neoplasms; Uterine Cervical Diseases	Details
11C-BF-227	11C-BF-227; [11C]BF-227	Phase 2 Clinical	Tohoku University	Diagnostic agents	Details
Pittsburgh Compound B	[11C]PIB; [11C]6-OH-BTA-1; 11C-PIB	Phase 2 Clinical	Ge Healthcare, The University Of Utah, University Of Pittsburgh, Uppsala Universitet	Alcoholism; Alzheimer Disease; Brain Concussion; Breast Neoplasms; Dementia; Ovarian Neoplasms; Parkinson Disease	Details
Zervimesine fumarate	SV-119; CT-1812	Phase 2 Clinical	Cogrx	Alzheimer Disease; Cognition Disorders; Lewy Body Disease; Macular Degeneration	Details
[18F]THK-5105	[18F]THK-5105	Phase 2 Clinical	Tohoku University	Alzheimer Disease	Details
Edonerpic	T-817 MA	Phase 2 Clinical	Fujifilm Group, Toyama Chemical Co Ltd	Alzheimer Disease; Cognitive Dysfunction; Hepatic Insufficiency	Details
ABvac-40	ABvac-40	Phase 2 Clinical	Araclon Biotech Sl	Alzheimer Disease; Cognitive Dysfunction	Details
TML-6	TML-6	Phase 2 Clinical	Merry Life Biomedical Co Ltd	Alzheimer Disease	Details
PHENOGENE-1A		Phase 2 Clinical	PhenoNet Inc	Alzheimer Disease; Amyotrophic Lateral Sclerosis	Details
PK-051	PK051; PK-051	Phase 2 Clinical	PharmaKure Ltd	Alzheimer Disease; Cognitive Dysfunction	Details
PRI-002	RD-2; PRI-002	Phase 2 Clinical	Priavoid, PRInnovation GmbH	Alzheimer Disease; Cognitive Dysfunction	Details
18F-92	18F-92	Phase 2 Clinical	First Affiliated Hospital Of Fujian Medical University	Alzheimer Disease	Details
OAB-14	OAB-14	Phase 2 Clinical	Shenyang Pharmaceutical University	Alzheimer Disease	Details
Mivelsiran	ALN-APP	Phase 2 Clinical	Sirna Therapeutics Inc	Alzheimer Disease; Cerebral Amyloid Angiopathy	Details
SHR-1707	SHR-1707	Phase 2 Clinical	Shanghai Hengrui Pharmaceutical Co Ltd	Alzheimer Disease	Details
BEY-2153	BEY-2153	Phase 2 Clinical	Beyondbio Inc	Alzheimer Disease	Details
Ezeprogind	AZP-2006	Phase 2 Clinical	Alzprotect, Inserm	Alzheimer Disease; Supranuclear Palsy, Progressive	Details
[18F]THK-5117	[18F]THK-5117	Phase 2 Clinical	Tohoku University	Alzheimer Disease	Details
AD-35	AD-35	Phase 2 Clinical	Zhejiang Hisun Pharmaceutical Co Ltd	Alzheimer Disease	Details
APH-1105	APH-1105	Phase 2 Clinical	Aphios Corporation	Alzheimer Disease; Dementia	Details
RIV-1061-IR	RIV-1061; RIV-1061-IR	Phase 1 Clinical	Revivo Therapeutics	Alzheimer Disease; Cognition Disorders	Details
A ß antibody Fab		Phase 1 Clinical	Eli Lilly And Company	Alzheimer Disease	Details
MDR-1339	DBT-1339; MDR-1339	Phase 1 Clinical	Medifron	Alzheimer Disease	Details
chimeric fusion protein (Attralus/University of Limoges)	AT-03 (Attralus)	Phase 1 Clinical	Universite De Limoges	Amyloidosis	Details
ADx-001		Phase 1 Clinical	University Of Houston	Alzheimer Disease; Dementia	Details
ALZ-101	ALZ-101	Phase 1 Clinical	Alzinova AB	Alzheimer Disease; Dementia	Details
PRX-012	PRX-012	Phase 1 Clinical	Prothena	Alzheimer Disease	Details
PMN-310	huPMN-310; PMN-310	Phase 1 Clinical	ProMIS Neurosciences Inc	Alzheimer Disease; Amyotrophic Lateral Sclerosis; Multiple System Atrophy	Details
AK-152	AK152; AK-152	Phase 1 Clinical		Alzheimer Disease	Details
AA-001	AA-001; AA001	Phase 1 Clinical	Beijing Zhiyuan Hongsheng Biopharmaceutical Co Ltd	Alzheimer Disease; Cognitive Dysfunction	Details
ION-269	ION-269; ION269	Phase 1 Clinical	Ionis Pharmaceuticals Inc	Alzheimer Disease; Down Syndrome	Details
ALIA-1758	ABBV-1758; ALIA-1758	Phase 1 Clinical	Johnson & Johnson Innovative Medicine	Alzheimer Disease	Details
CM-383	CM383; CM-383	Phase 1 Clinical	Keymed Biosciences Co Ltd	Alzheimer Disease; Cognitive Dysfunction	Details
AS-603	S-603; AS-603; AS-S603	Phase 1 Clinical	Amyloid Solution Inc	Alzheimer Disease	Details
AV-1959R/AV-1980R	1959R + 1980R; AV 1959R + AV 1980R	Phase 1 Clinical	Nuravax	Alzheimer Disease	Details
Abeta42 antibody (Lilly)		Phase 1 Clinical	Eli Lilly And Company	Alzheimer Disease	Details
Anatabine citrate	RCP-006	Clinical	Rock Creek, Roskamp Institute	Alzheimer Disease; Inflammation; Smoking Cessation; Thyroiditis, Autoimmune; Tobacco Use Disorder	Details
123I-ABC-577	123I-ABC-577	Clinical	Nihon Medi-Physics Co Ltd	Diagnostic agents	Details
Tarenflurbil spraygel (MIKA Pharma)		Clinical	Galen Ltd, Mika Pharma Gmbh	Arthritis, Rheumatoid; Dermatitis, Atopic; Inflammation; Pain; Skin Diseases	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Donanemab	LY-3002813-IV; LY-3002813; LY-3002813-SC	Approved	Eli Lilly And Company	Kisunla, 记能达	United States	Alzheimer Disease	Eli Lilly And Company	2024-07-02	Alzheimer Disease; Brain Diseases; Central Nervous System Diseases; Cognition Disorders; Cognitive Dysfunction; Dementia; Mental Disorders; Nervous System Diseases; Neurocognitive Disorders; Neurodegenerative Diseases; Tauopathies	Details
Flutemetamol (18F)	18F-GE067; AH-110690; GE-067	Approved	Ge Healthcare	Vizamyl	United States	Contrast agents	Ge Healthcare	2013-10-25	Alzheimer Disease; Atherosclerosis; Breast Neoplasms; Cognition Disorders; Cognitive Dysfunction; Contrast agents; Dementia; Diagnostic agents; Hydrocephalus, Normal Pressure	Details
Inositol	4L6452S749	Approved		Nicosit					Anovulation; Anxiety; Bronchopulmonary Dysplasia; Carcinoma, Non-Small-Cell Lung; Depression; Diabetic Neuropathies; Glucose Intolerance; Hyperandrogenism; Infant, Newborn, Diseases; Insulin Resistance; Lung Neoplasms; Metabolic Diseases; Polycystic Ovary Syndrome; Precancerous Conditions; Premature Birth; Retinopathy of Prematurity	Details
Immune globulin 10% (Grifols)	KIg-10; TAL-05-0002	Approved	Bayer AG	Gamunex, Gammaked	United States	Purpura, Thrombocytopenic, Idiopathic; Immunologic Deficiency Syndromes; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	null	2003-08-27	Agammaglobulinemia; Anemia, Sickle Cell; Anxiety Disorders; Autoimmune Diseases; Common Variable Immunodeficiency; Corneal Neovascularization; Coronavirus Disease 2019 (COVID-19); Immunologic Deficiency Syndromes; Kidney Failure, Chronic; Muscular Diseases; Myasthenia Gravis; Neuralgia; Obsessive-Compulsive Disorder; Pain; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Postural Orthostatic Tachycardia Syndrome; Primary Immunodeficiency Diseases; Purpura, Thrombocytopenic, Idiopathic; Reflex Sympathetic Dystrophy; Severe Combined Immunodeficiency; Tibial Fractures; Wiskott-Aldrich Syndrome	Details
Florapronol (18F)	18F-FC-119(S); 18F-FC-119S	Approved	Futurechem, Korea Institute Of Radiological And Medical Sciences	Alzavue					Alzheimer Disease	Details
Aducanumab	BIIB-037; NI-10; BART	Approved	Neurimmune Ag	ADUHELM	United States	Alzheimer Disease	Biogen Inc	2021-06-07	Alzheimer Disease; Cognitive Dysfunction; Dementia	Details
Procaine Hydrochloride/Vitamin B6/Inositol		Approved							Arteriosclerosis; Dyspepsia; Menopausal symptoms; Neurocirculatory Asthenia	Details
Inositol/Vitamin B1/Vitamin B2		Approved							Liver Diseases	Details
L-Lysine hydrochloride/Cyanocobalamin/Inositol		Approved		兴邦					Malnutrition	Details
Immune Globulin Subcutaneous (Human) (Octapharma)		Approved	Octapharma	Cutaquig, Octanorm, Gammanorm	United States	Immunologic Deficiency Syndromes	null	2018-08-02	Dermatomyositis; Immunologic Deficiency Syndromes; Primary Immunodeficiency Diseases	Details
Florbetaben (18F)	AV-1; ZK-6013443; BAY-949172; 18F-AV-1; MNI-815; BAY 94-9172; UNII-TLA7312TOI; 18F-AV1/ZK; AV-1/ZK	Approved	Avid Radiopharmaceuticals Inc	欧韦宁, Neuraceq	EU	Alzheimer Disease	Life Radiopharma Berlin Gmbh	2014-02-20	Alzheimer Disease; Amyloidosis; Contrast agents; Dementia; Down Syndrome; Hyponatremia; Immunoglobulin Light-chain Amyloidosis; Lewy Body Disease; Parkinson Disease; Supranuclear Palsy, Progressive	Details
Lecanemab	BAN-2401	Approved	Bioarctic Neuroscience	Leqembi, LEQEMBI, 乐意保	United States	Alzheimer Disease	Eisai Inc	2023-01-06	Alzheimer Disease; Cognitive Dysfunction; Dementia	Details
Florbetapir(18F)	MNI-798; AV-45	Approved	Eli Lilly And Company	艾美维, Amyvid	United States	Alzheimer Disease	Avid Radiopharmaceuticals Inc	2012-04-06	Alzheimer Disease; Cognitive Dysfunction; Contrast agents; Frontotemporal Dementia; Glioblastoma; Lewy Body Disease; Neurodegenerative Diseases; Parkinson Disease	Details